Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Silence Therapeutics (SLN) Interest & Investment Income (2020 - 2024)

Silence Therapeutics' Interest & Investment Income history spans 5 years, with the latest figure at $1.3 million for Q3 2024.

  • On a quarterly basis, Interest & Investment Income fell 50.82% to $1.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $6.7 million, a 410.59% increase, with the full-year FY2023 number at $1.8 million, up 14.0% from a year prior.
  • Interest & Investment Income hit $1.3 million in Q3 2024 for Silence Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for SLN hit a ceiling of $189.7 million in Q3 2020 and a floor of -$1.3 billion in Q4 2020.
  • Historically, Interest & Investment Income has averaged -$66.6 million across 5 years, with a median of $842481.2 in 2022.
  • The widest YoY moves for Interest & Investment Income: up 1150.29% in 2022, down 177430.05% in 2022.
  • Tracing SLN's Interest & Investment Income over 5 years: stood at -$1.3 billion in 2020, then soared by 100.0% to $2696.0 in 2021, then crashed by 177430.05% to -$4.8 million in 2022, then soared by 165.01% to $3.1 million in 2023, then plummeted by 58.99% to $1.3 million in 2024.
  • Business Quant data shows Interest & Investment Income for SLN at $1.3 million in Q3 2024, $1.3 million in Q2 2024, and $1.0 million in Q1 2024.